A Legacy of Innovation in Healing

The story of NADH is intricately linked to the story of the Birkmayer family. It began in post war Vienna at the Hospital for the Brain Injured "Wiener Hirnverletzten-Lazarett". There the young professor Walther Birkmayer saw over 3,000 brain injured patients as head physician. Grasping the importance of neuro-rehabilitation as a special discipline, he began a journey to explore the neurobiological reactive mechanisms within the brain. His observations led to the realization that injuries must create an imbalance between various reactor substances or neurotransmitters, resulting in a wide range of patient behaviors or symptoms.

His subsequent research with Parkinson's patients during the late 50's and early 60's, using L-Dopa, the precursor to the substance dopamine, led to one of the crucial events of neurology. He succeeded in demonstrating that a pharmacological effect could be counteracted by another chemical substance producing a specific physiological or psychic result. In the years that followed, Dr. Walther Birkmayer was to receive four honorary Doctorates from leading European institutions in recognition of his outstanding lifetime contributions. He was also highly regarded by his patients for his help and his humanity.

Walther's son Georg also became a doctor. After fighting at the forefront of cancer research, Georg was to follow his father, making his own contribution to the development of neuro-rehabilitative therapies. He went on to discover and implement the therapeutic usage of NADH or coenzyme 1.

In 1993, Dr. Georg Birkmayer, M.D., Ph.D., now also a renowned biochemical researcher and director of the Birkmayer Institute for Parkinson Therapy, founder and chairman of Birkmayer Pharmaceuticals Inc. (New York) and Birkmayer Laboratories (Vienna, Austria), developed the first and only stable and absorbable oral tablet form of NADH. His discovery, recognized with worldwide patents, made NADH available to the general public as a nutritional supplement, licensed and only available under the brand name ENADA®.

Research continues in the U.S.A. and abroad to explore ENADA®'s full potential. FDA approved clinical trials are currently being conducted under the auspices of leading American research hospitals.